Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 723 JPY 7.59% Market Closed
Market Cap: 10.6B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Perseus Proteomics Inc
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Other Current Assets
ÂĄ21.3m
CAGR 3-Years
45%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Other Current Assets
ÂĄ1.4B
CAGR 3-Years
41%
CAGR 5-Years
42%
CAGR 10-Years
32%
PeptiDream Inc
TSE:4587
Other Current Assets
ÂĄ1B
CAGR 3-Years
46%
CAGR 5-Years
29%
CAGR 10-Years
35%
Takara Bio Inc
TSE:4974
Other Current Assets
ÂĄ2.7B
CAGR 3-Years
28%
CAGR 5-Years
27%
CAGR 10-Years
6%
Pharma Foods International Co Ltd
TSE:2929
Other Current Assets
ÂĄ598m
CAGR 3-Years
8%
CAGR 5-Years
21%
CAGR 10-Years
15%
C
Cuorips Inc
TSE:4894
Other Current Assets
ÂĄ28.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
10.3B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
719.16 JPY
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Other Current Assets?
Other Current Assets
21.3m JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Other Current Assets amounts to 21.3m JPY.

What is Perseus Proteomics Inc's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
-16%

Over the last year, the Other Current Assets growth was 38%. The average annual Other Current Assets growth rates for Perseus Proteomics Inc have been 45% over the past three years , -16% over the past five years .

Back to Top